PUMA BIOTECHNOLOGY, INC. (PBYI)
Pharmaceutical Preparations · Healthcare · $365M
Intrinsic Value (Consensus)
$8.61
Current Price
$7.17
Margin of Safety
+20.1%
20.1% Below Intrinsic Value
Value: $9
Price: $7
Valuation Model Estimates
Current Price: $7.17
DCF (Discounted Cash Flow)
$10.40
Graham Number
$5.93
Earnings Power Value
$5.92
Relative Value (P/E)
$12.20
Dividend Discount Model
Not applicable
—
Consensus Value
$8.61
Model Assumptions
Discount Rate
10.3%
Growth Rate
2.0%
Terminal Growth
2.5%
Risk-Free Rate
4.3%
Discount rate derived from CAPM (risk-free rate + beta × market risk premium). Growth rate based on trailing earnings growth, capped at 20%.
Health Score
B
69
Profitability
22/25
Strength
24/25
Valuation
19/25
Growth
4/25
Financial Health Signals
Declining revenue — top line is shrinking
Strong profitability — ROE of 24% (above 20% is excellent)
Low debt — conservative balance sheet
High free cash flow yield (11.4%) — generating lots of cash relative to price
Key Financials
- EPS (TTM)
- $0.61
- EPS (Forward)
- $0.62
- Book Value
- $2.56
- P/E Ratio
- 20.0
- Forward P/E
- 19.6
- PEG Ratio
- —
- ROE
- 23.9%
- Debt/Equity
- 17%
- Revenue Growth
- -0.9%
- Earnings Growth
- 2.0%
- Dividend Yield
- N/A
- Beta
- 1.00
Similar Stocks (Healthcare)
ABEOAbeona Therapeutics ...
$37.06+300%
ABUSArbutus Biopharma Co...
$18.93+300%
ADVBAdvanced Biomed Inc....
$26.66+300%
AGENAgenus Inc.
$20.19+300%
ATRAAtara Biotherapeutic...
$41.43+300%
Data last updated: 2026-06-16
Source: Yahoo Finance